Literature DB >> 30080059

The influence of anxiety sensitivity on opioid use disorder treatment outcomes.

Catherine Baxley1, Jeremiah Weinstock1, Patrick J Lustman2, Annie A Garner1.   

Abstract

Given the high rates of relapse among patients with opioid use disorder (OUD), it is crucial to identify modifiable risk factors for negative treatment outcomes. Anxiety sensitivity (AS) is 1 such risk factor that may be associated with negative OUD treatment outcomes. The present study examined the potential impact of AS on the withdrawal process, subsequent treatment engagement, and relapse among individuals with OUD. Adults undergoing inpatient detoxification (N = 90) completed self-report and researcher-administered questionnaires on Day 4 of a 5-day buprenorphine-assisted detoxification protocol, and 1 month later a follow-up evaluation assessed treatment engagement and relapse. Although 68% of the sample engaged in subsequent treatment, 76% demonstrated poor adherence. Over half the sample (57%) reported opioid relapse 1 month later. Results revealed that greater AS and younger age predicted greater fear of withdrawal during detoxification. Contrary to the research hypotheses, AS was not a significant predictor of other treatment outcomes; rather, fear of withdrawal and prior number of opioid detoxifications predicted greater subjective withdrawal severity. During detoxification, younger age was related to greater cravings, and being a male was associated with a higher likelihood of receiving prescription anxiolytics. Following detoxification treatment, referral to residential treatment predicted greater treatment engagement, whereas greater opioid craving, number of days in an uncontrolled environment, and any nonopioid substance use postdischarge predicted greater opioid relapse. Failure to find a relationship between AS and the withdrawal process is potentially a function of the buprenorphine protocol. Overall, findings may have important implications for the treatment of OUD. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30080059     DOI: 10.1037/pha0000215

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  8 in total

Review 1.  Comorbidity of opioid-related and anxiety-related symptoms and disorders.

Authors:  Kirsten J Langdon; Kathrine Dove; Susan Ramsey
Journal:  Curr Opin Psychol       Date:  2019-01-04

2.  Craving of prescription opioids among veterans with chronic pain.

Authors:  Tiffany Toor; Emily Murphy; Alan N Simmons; Sarah Palyo; Sara C Librodo; Irina A Strigo
Journal:  Pain       Date:  2022-01-28       Impact factor: 7.926

3.  Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.

Authors:  Rosemarie A Martin; Damaris J Rohsenow; Jennifer W Tidey
Journal:  J Subst Abuse Treat       Date:  2019-06-10

4.  Predictive variables of prescription opioid misuse in patients with chronic noncancer pain. Development of a risk detection scale: A registered report protocol.

Authors:  Carmen Ramírez-Maestre; Alicia E López-Martínez; Rosa Esteve
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

5.  Laboratory-induced stress and craving predict opioid use during follow-up among individuals with prescription opioid use disorder.

Authors:  Tanya C Saraiya; Amber M Jarnecke; Jennifer Jones; Delisa G Brown; Kathleen T Brady; Sudie E Back
Journal:  Drug Alcohol Depend       Date:  2021-05-21       Impact factor: 4.852

6.  Sex differences in factors predicting post-treatment opioid use.

Authors:  Jordan P Davis; David Eddie; John Prindle; Emily R Dworkin; Nina C Christie; Shaddy Saba; Graham T DiGuiseppi; John D Clapp; John F Kelly
Journal:  Addiction       Date:  2021-01-22       Impact factor: 7.256

7.  Depletion of the Microbiome Alters the Recruitment of Neuronal Ensembles of Oxycodone Intoxication and Withdrawal.

Authors:  Sierra Simpson; Adam Kimbrough; Brent Boomhower; Rio McLellan; Marcella Hughes; Kokila Shankar; Giordano de Guglielmo; Olivier George
Journal:  eNeuro       Date:  2020-05-21

8.  Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management.

Authors:  Jumi Hayaki; Micah T Conti; Genie L Bailey; Debra S Herman; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2021-01-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.